COVID-19与肺:从间质性肺炎到肺纤维化

Q4 Health Professions
Š. Laššán, M. Laššánová
{"title":"COVID-19与肺:从间质性肺炎到肺纤维化","authors":"Š. Laššán, M. Laššánová","doi":"10.36290/far.2022.016","DOIUrl":null,"url":null,"abstract":"The novel coronavirus-induced disease led to a pandemic that poses a global threat to human health. The most common cause of hospitalisation for COVID-19 is interstitial pneumonia that may be complicated by Acute Respiratory Distress Syndrome (ARDS). The monitoring of patients who have recovered from COVID-associated pneumonia demonstrates that the significant reduction in diffuse lung capacity and associated fibrotic signs in the lung parenchyma are factors associated with a negative prognosis. Thus, the long-term consequences of COVID-19 appear crucial. Risk factors, histopathological characterization, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood. This review addresses underlying pathobiological mechanisms and the possible predictors which might lead to the development of fibrotic lung remodeling. Potential therapeutic modalities include anti-fibrotic drugs, prolonged use of corticosteroids, other anti-inflammatory and immunosuppressive drugs, spironolactone, azithromycine, with further multiple novel compounds under investigation. Copyright © 2022, SOLEN s.r.o.. All rights reserved.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 and the lung: from interstitial pneumonia to pulmonary fibrosis\",\"authors\":\"Š. Laššán, M. Laššánová\",\"doi\":\"10.36290/far.2022.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The novel coronavirus-induced disease led to a pandemic that poses a global threat to human health. The most common cause of hospitalisation for COVID-19 is interstitial pneumonia that may be complicated by Acute Respiratory Distress Syndrome (ARDS). The monitoring of patients who have recovered from COVID-associated pneumonia demonstrates that the significant reduction in diffuse lung capacity and associated fibrotic signs in the lung parenchyma are factors associated with a negative prognosis. Thus, the long-term consequences of COVID-19 appear crucial. Risk factors, histopathological characterization, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood. This review addresses underlying pathobiological mechanisms and the possible predictors which might lead to the development of fibrotic lung remodeling. Potential therapeutic modalities include anti-fibrotic drugs, prolonged use of corticosteroids, other anti-inflammatory and immunosuppressive drugs, spironolactone, azithromycine, with further multiple novel compounds under investigation. Copyright © 2022, SOLEN s.r.o.. All rights reserved.\",\"PeriodicalId\":39116,\"journal\":{\"name\":\"Klinicka Farmakologie a Farmacie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinicka Farmakologie a Farmacie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36290/far.2022.016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka Farmakologie a Farmacie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36290/far.2022.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0

摘要

新型冠状病毒引发的疾病导致了一场对人类健康构成全球威胁的大流行。新冠肺炎最常见的住院原因是间质性肺炎,可能并发急性呼吸窘迫综合征(ARDS)。对新冠肺炎相关肺炎康复患者的监测表明,弥漫性肺容量的显著降低和肺实质中相关的纤维化迹象是与不良预后相关的因素。因此,新冠肺炎的长期后果似乎至关重要。COVID-19后肺纤维化的危险因素、组织病理学特征、患病率和管理尚不清楚。这篇综述探讨了潜在的病理生物学机制和可能导致纤维化肺重塑发展的预测因素。潜在的治疗方式包括抗纤维化药物、长期使用皮质类固醇、其他抗炎和免疫抑制药物、螺内酯、叠氮霉素,以及正在研究的多种新化合物。版权所有©2022,SOLEN s.r.o.。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19 and the lung: from interstitial pneumonia to pulmonary fibrosis
The novel coronavirus-induced disease led to a pandemic that poses a global threat to human health. The most common cause of hospitalisation for COVID-19 is interstitial pneumonia that may be complicated by Acute Respiratory Distress Syndrome (ARDS). The monitoring of patients who have recovered from COVID-associated pneumonia demonstrates that the significant reduction in diffuse lung capacity and associated fibrotic signs in the lung parenchyma are factors associated with a negative prognosis. Thus, the long-term consequences of COVID-19 appear crucial. Risk factors, histopathological characterization, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood. This review addresses underlying pathobiological mechanisms and the possible predictors which might lead to the development of fibrotic lung remodeling. Potential therapeutic modalities include anti-fibrotic drugs, prolonged use of corticosteroids, other anti-inflammatory and immunosuppressive drugs, spironolactone, azithromycine, with further multiple novel compounds under investigation. Copyright © 2022, SOLEN s.r.o.. All rights reserved.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Klinicka Farmakologie a Farmacie
Klinicka Farmakologie a Farmacie Health Professions-Pharmacy
CiteScore
0.30
自引率
0.00%
发文量
20
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信